GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Operating Income

LMAT (LeMaitre Vascular) Operating Income : $52.3 Mil (TTM As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is LeMaitre Vascular Operating Income?

LeMaitre Vascular's Operating Income for the three months ended in Dec. 2024 was $12.9 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $52.3 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. LeMaitre Vascular's Operating Income for the three months ended in Dec. 2024 was $12.9 Mil. LeMaitre Vascular's Revenue for the three months ended in Dec. 2024 was $55.7 Mil. Therefore, LeMaitre Vascular's Operating Margin % for the quarter that ended in Dec. 2024 was 23.07%.

Good Sign:

LeMaitre Vascular Inc operating margin is expanding. Margin expansion is usually a good sign.

LeMaitre Vascular's 5-Year average Growth Rate for Operating Margin % was 2.10% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LeMaitre Vascular's annualized ROC % for the quarter that ended in Dec. 2024 was 18.08%. LeMaitre Vascular's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 60.48%.


LeMaitre Vascular Operating Income Historical Data

The historical data trend for LeMaitre Vascular's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular Operating Income Chart

LeMaitre Vascular Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.32 36.43 29.94 37.20 52.26

LeMaitre Vascular Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.21 11.87 14.38 13.15 12.85

LeMaitre Vascular Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LeMaitre Vascular  (NAS:LMAT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LeMaitre Vascular's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=51.416 * ( 1 - 20.23% )/( (227.992 + 225.602)/ 2 )
=41.0145432/226.797
=18.08 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=377.025 - 25.144 - ( 123.889 - max(0, 29.343 - 227.116+123.889))
=227.992

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=551.817 - 26.493 - ( 299.722 - max(0, 30.607 - 402.192+299.722))
=225.602

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

LeMaitre Vascular's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=70.712/( ( (41.119 + max(76.607, 0)) + (41.568 + max(74.544, 0)) )/ 2 )
=70.712/( ( 117.726 + 116.112 )/ 2 )
=70.712/116.919
=60.48 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.269 + 57.085 + 13.873) - (25.144 + 0 + 1.476)
=76.607

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(30.063 + 55.942 + 16.465) - (26.493 + 0 + 1.433)
=74.544

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

LeMaitre Vascular's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=12.854/55.717
=23.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


LeMaitre Vascular Operating Income Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


LeMaitre Vascular Business Description

Traded in Other Exchanges
Address
63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Executives
Trent G Kamke officer: Senior V. P., Operations 61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Lawrence J Jasinski director SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
Bridget A Ross director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
David B Roberts director, officer: CFO and Director 55 BRADFORD STREET, NEEDHAM MA 02492
George W Lemaitre director, 10 percent owner, officer: Chairman, President and CEO 342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
John A Roush director C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Pellegrino Joseph P Jr officer: Executive V.P. Finance 68 BEACON STREET, BOSTON MA 02108
Michael H Thomas director P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer officer: President, International OP AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas officer: VP of Sales, The Americas C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W director, officer: V.P., Human Resources,Director 8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays director C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden officer: VP, North American Sales 236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr director HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199